Pierian Biosciences

What Pierian Biosciences does

Pierian Biosciences is a privately held clinical diagnostics and laboratory services company that develops functional assays for personalized cancer treatment selection. The company, formerly known as DiaTech Oncology, is incorporated in Delaware with US headquarters in Franklin, Tennessee, and an additional research laboratory in Liverpool, United Kingdom. Its portfolio comprises three proprietary platforms: ChemoINTEL™, a 384-well imaging-based chemosensitivity assay measuring real-time kinetic apoptosis in tumor cells exposed to cytotoxic or targeted agents; ImmunoINTEL™, a plate-based flow cytometry platform profiling tumor and immune populations to guide immunotherapy selection; and PathwayINTEL (formerly CEER), a functional proteomic assay identifying oncogenic drivers to inform targeted and biologic therapy choice.

The company's business model is built on three revenue streams: (1) laboratory diagnostic services billed to oncologists and cancer treatment providers on an assay-by-assay basis; (2) clinical trial support services for biopharma spanning Pre-Clinical through Phase IV, including drug screening and combination evaluation; and (3) pharmaceutical partnership services for companion diagnostic development, patient stratification, and FDA Premarket Approval support. Pricing is not publicly disclosed, with services quoted per assay and engagement. The company pursues a sales-led, enterprise go-to-market through direct engagement with healthcare providers, partnership arrangements with academic medical centers and NHS facilities, and biopharma collaborations, while maintaining an active presence at scientific conferences such as SITC and AACR.

As of the most recent inputs, Pierian employs between 1 and 10 people, is actively operating, has stated $42 million of capital deployed into UK lab development plus a further £25 million planned for commercialization, and has signed a flagship multi-year research collaboration with The Clatterbridge Cancer Centre NHS Foundation Trust to develop algorithms for ovarian cancer treatment innovation. Healthcare regulators oversee its operations through HIPAA (PHI handling ceased March 2016) and GDPR (EU Data Controller) compliance frameworks. The diagnostic platforms are positioned to deliver results within roughly 72 hours of tissue arrival, supporting treatment-directing decisions for oncologists treating solid tumors, hematologic cancers, and select autoimmune diseases.

Name

Pierian Biosciences

Legal name

Pierian Biosciences

Website

https://pierianbio.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Pierian Biosciences is a privately held clinical diagnostics company that develops functional assays (ChemoINTEL™, ImmunoINTEL™, PathwayINTEL) using flow cytometry and kinetic imaging to guide personalized cancer treatment selection for oncologists, biopharmaceutical sponsors, and academic medical centers.

Ownership category

akta.pro rank

Product category

Personalized Cancer Diagnostics

NAICS

Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industry

Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Cancer diagnostic testing
• Personalized cancer diagnostics
• Chemosensitivity assays
• Tumor profiling services
• Clinical trial diagnostics

Headquarters

HQ city

Brentwood

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Laboratory Diagnostic Services: The company provides laboratory testing services for physicians and healthcare professionals, using patient tumor samples to generate treatment-directing diagnostic information. Tests include ChemoINTEL™ and ImmunoINTEL™ assays that guide personalized cancer treatment selection.
2. Clinical Trial Support Services: Pierian Biosciences provides biopharmaceutical support services for Pre-Clinical through Phase IV clinical trials, including drug screening and novel drug combination evaluation.
3. Pharmaceutical Partnership Services: Collaboration with pharmaceutical companies for companion diagnostic development, patient stratification for clinical trials, and regulatory support for FDA Premarket Approval applications of IVD products.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Pierian Biosciences is a diagnostic development and laboratory service company that delivers treatment-directing assays for personalized cancer and auto-immune disease therapy selection. The company offers three proprietary assay platforms — ChemoINTEL™ (functional chemosensitivity testing), ImmunoINTEL™ (immune-profiling via flow cytometry), and PathwayINTEL (functional proteomic profiling) — to oncologists, pharmaceutical sponsors, and academic research partners through its US and UK laboratories. Pierian also provides pharmaceutical partnership services including companion diagnostic development, clinical trial patient stratification, and regulatory support for FDA Premarket Approval applications.

Product overview

Pierian Biosciences offers a portfolio of three distinct diagnostic platforms for personalized cancer treatment: ChemoINTEL™ (a functional chemosensitivity assay measuring apoptotic response to predict chemotherapy effectiveness), ImmunoINTEL™ (a flow cytometry-based platform profiling the tumor microenvironment and immune landscape to guide immunotherapy selection), and PathwayINTEL (a functional proteomic profiling assay identifying oncogenic drivers for targeted and biologic therapy selection). Together, these platforms enable healthcare providers to personalize treatment for patients with cancer and auto-immune diseases.

Differentiator

Problem solved

Functional benefit

Brands

• CHEMOINTEL™: A functional multi-parametric chemosensitivity assay providing actionable information guiding the selection of the most effective cytotoxic, targeted, or combination therapy.
• IMMUNOINTEL™

Products and services

• ChemoINTEL™ A functional multi-parametric chemosensitivity assay that measures real-time kinetic molecular and morphologic apoptotic response in isolated tumor cells induced by cytotoxic agents, targeted molecular therapeutics, biologics, or combination therapy. Uses an automated 384-well based imaging platform. Designed for oncologists seeking actionable information to guide selection of the most effective cytotoxic, targeted, or combination therapy.
• ImmunoINTEL™ A comprehensive flow cytometry-based functional immuno-assay providing phenotypic characterization and quantitative functional interrogation of tumor and immune populations within a tumor sample. Profiles targetable receptors and ligands (ICP and ICP-L expression) to guide selection of the most appropriate immunotherapeutic. Uses a highly-automated, plate-based flow cytometry workflow for high-throughput reproducible processing of cells from dissociated solid tumors, hematologic cancers, and auto-immune diseases.
• PathwayINTEL A functional proteomic profiling assay providing quantitative information on the expression and activation status of proteins to identify the true oncogenic 'driver' and enable selection of the most appropriate targeted and/or biologic therapy for cancer patients.

Quantifiable outcome

• Results delivered within 72 hours of tissue arrival in lab

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• The Clatterbridge Cancer Centre NHS Foundation TrustcoreStrategic or Co-development Partner · 28 September 2022Groundbreaking collaboration for ovarian cancer treatment innovation. Pierian Biosciences is the Biotechnology Company and Sponsor of the research and development study, with The Clatterbridge Cancer Centre acting as Clinical Research Organisation (CRO). The collaboration focuses on developing cutting-edge algorithms for advancing understanding and management of Ovarian Cancer. The study involves patient screening, laboratory operations coordination, and collection of de-identified patient clinical information including treatment regimens, adverse reactions, and clinical outcomes.
• Harrogate International AdvisorsminorImplementation/ SI/ Consulting PartnerMandated to Harrogate International Advisors for the inward investment project. The advisory firm facilitated Pierian Biosciences' expansion into Liverpool, working with local stakeholders including city council, academics, and oncology specialists.
• Liverpool Science ParkcoreStrategic or Co-development PartnerUK laboratory located within Liverpool Science Park facilities. The Science Park provides laboratory facilities of the highest standard for Pierian's diagnostic work and research activities.

Scale indicators2 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Foundation Medicine: Foundation Medicine's FoundationOne CDx is the dominant FDA-approved NGS companion diagnostic and the reference molecular-treatment-selection test used by oncologists and pharma — the established incumbent Pierian functionally competes with in the oncology therapy-selection workflow.
• Tempus: Tempus combines molecular profiling (DNA/RNA sequencing) with clinical data and AI for oncology therapy selection and pharma trial enablement — overlapping Pierian's Clinico-omics and pharma partnership value proposition at much larger scale.
• NeoGenomics: NeoGenomics runs a large oncology-focused clinical reference laboratory serving community oncologists with a broad menu of molecular and conventional oncology tests — overlapping Pierian's direct sales to oncologists and pharma clinical-trial lab services.
• Caris Life Sciences: Caris offers multi-omic molecular profiling (MI Profile) plus AI-driven Caris Assure for therapy selection across oncology — a broader, well-capitalized portfolio player addressing the same oncologist treatment-selection decision that Pierian's INTEL™ platforms address.
• Natera: Natera operates personalized molecular diagnostic tests across oncology (Signatera MRD), transplant, and women's health — a broad portfolio incumbent pursuing the same oncologist and pharma customer base for therapy-selection and trial-support diagnostics.
• Guardant Health: Guardant is a publicly-traded leader in liquid-biopsy ctDNA-based therapy-selection testing (Guardant360); Pierian board member Dr. Craig Eagle is Guardant's CMO, underscoring the adjacency to Pierian's functional assay franchise for oncology therapy selection.
• Exact Sciences: Exact Sciences (Cologuard, Oncotype, TheraLink) is a major publicly-traded cancer diagnostics company pursuing oncology therapy-selection and screening adjacencies, with substantially greater scale, reimbursement footprint, and FDA-cleared products than Pierian.

Emerging players

• Personalis: Personalis offers tumor-informed molecular profiling (NeXT Personal) for oncology therapy selection and MRD — a smaller, more specialized competitor focused on next-generation sequencing-based decision support in oncology, with similar pharma CDx ambitions.

Direct peers

• Epic Sciences: Epic Sciences combines single-cell functional characterization of circulating tumor cells with downstream molecular profiling, intersecting Pierian's single-cell flow-cytometry ImmunoINTEL™ approach and serving pharma for patient stratification and therapy-selection diagnostics.
• Champions Oncology: Champions Oncology offers functional personalized oncology diagnostics via its TumorGraft platform that measures ex-vivo tumor response to therapeutics — the same ex-vivo functional-testing model that Pierian delivers through ChemoINTEL™ and ImmunoINTEL™, serving oncologists and pharma trial customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pierian-biosciences
• Xx.com/pierianbio
• Facebookfacebook.com/pierianbio

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pierian Biosciences